Compare Novartis AG (NVS) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Synchrony Financial — how do they compare? Novartis AG trades at $152.4 (market cap $295.37B), while Synchrony Financial trades at $78.37 (market cap $25.53B). The key difference: Novartis AG is far larger — about 11.6× Synchrony Financial's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| NVS | SYF | |
|---|---|---|
Market Cap | $295.37B | $25.53B |
Sector | Health | Financials |
52-Week High | $168.62 | $88.47 |
52-Week Low | $119.31 | $63.78 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | 1.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
